- NCIt
- C7049
Loading cancer entity…
Loading cancer entity…
Clinical trials
146 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02613988 | Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas | unknown | N/A | 100 | Asan Medical CenterOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT05333588 | The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme. | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT03025893 |
| A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme(STELLAR) |
| unknown |
| Phase 2 / Phase 3 |
| 100 |
| Amsterdam UMC, location VUmcOTHER |
| 1 |
| Apr 19, 2021 |
| clinicaltrials |
Data updated 23 days agoSource updated May 14, 2024source: clinicaltrials